PMID- 22242613
OWN - NLM
STAT- MEDLINE
DCOM- 20120522
LR  - 20240315
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Print)
IS  - 0036-5521 (Linking)
VI  - 47
IP  - 2
DP  - 2012 Feb
TI  - Rationale in diagnosis and screening of atrophic gastritis with stomach-specific 
      plasma biomarkers.
PG  - 136-47
LID - 10.3109/00365521.2011.645501 [doi]
AB  - BACKGROUND AND AIMS: Atrophic gastritis (AG) results most often from Helicobacter 
      pylori (H. pylori) infection. AG is the most important single risk condition for 
      gastric cancer that often leads to an acid-free or hypochlorhydric stomach. In 
      the present paper, we suggest a rationale for noninvasive screening of AG with 
      stomach-specific biomarkers. METHODS: The paper summarizes a set of data on 
      application of the biomarkers and describes how the test results could be 
      interpreted in practice. RESULTS: In AG of the gastric corpus and fundus, the 
      plasma levels of pepsinogen I and/or the pepsinogen I/pepsinogen II ratio are 
      always low. The fasting level of gastrin-17 is high in AG limited to the corpus 
      and fundus, but low or non-elevated if the AG occurs in both antrum and corpus. A 
      low fasting level of G-17 is a sign of antral AG or indicates high intragastric 
      acidity. Differentiation between antral AG and high intragastric acidity can be 
      done by assaying the plasma G-17 before and after protein stimulation, or before 
      and after administration of the proton pump inhibitors (PPI). Amidated G-17 will 
      rise if the antral mucosa is normal in structure. H. pylori antibodies are a 
      reliable indicator of helicobacter infection, even in patients with AG and 
      hypochlorhydria. CONCLUSIONS: Stomach-specific biomarkers provide information 
      about the stomach health and about the function of stomach mucosa and are a 
      noninvasive tool for diagnosis and screening of AG and acid-free stomach.
FAU - Agreus, Lars
AU  - Agreus L
AD  - Karolinska Institute, Center for Family and Community Medicine, Stockholm, 
      Sweden.
FAU - Kuipers, Ernst J
AU  - Kuipers EJ
FAU - Kupcinskas, Limas
AU  - Kupcinskas L
FAU - Malfertheiner, Peter
AU  - Malfertheiner P
FAU - Di Mario, Francesco
AU  - Di Mario F
FAU - Leja, Marcis
AU  - Leja M
FAU - Mahachai, Varocha
AU  - Mahachai V
FAU - Yaron, Niv
AU  - Yaron N
FAU - van Oijen, Martijn
AU  - van Oijen M
FAU - Perez Perez, Guillermo
AU  - Perez Perez G
FAU - Rugge, Massimo
AU  - Rugge M
FAU - Ronkainen, Jukka
AU  - Ronkainen J
FAU - Salaspuro, Mikko
AU  - Salaspuro M
FAU - Sipponen, Pentti
AU  - Sipponen P
FAU - Sugano, Kentaro
AU  - Sugano K
FAU - Sung, Joseph
AU  - Sung J
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Biomarkers)
RN  - 0 (Gastrins)
RN  - 60748-06-3 (gastrin 17)
RN  - 61536-72-9 (Pepsinogen C)
RN  - 9001-10-9 (Pepsinogen A)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
EIN - Scand J Gastroenterol. 2012 Dec;47(12):1525
MH  - Achlorhydria/blood/complications
MH  - Antibodies, Bacterial/blood
MH  - Biomarkers/*blood
MH  - Gastric Mucosa/microbiology/pathology/physiopathology
MH  - Gastrins/blood
MH  - Gastritis, Atrophic/*blood/*diagnosis/microbiology
MH  - Helicobacter Infections/*blood/*diagnosis/microbiology
MH  - Helicobacter pylori/immunology
MH  - Humans
MH  - Mass Screening
MH  - Pepsinogen A/blood
MH  - Pepsinogen C/blood
MH  - Stomach Neoplasms/complications/diagnosis/prevention & control
MH  - Vitamin B 12/pharmacokinetics
PMC - PMC3279132
EDAT- 2012/01/17 06:00
MHDA- 2012/05/23 06:00
PMCR- 2012/02/14
CRDT- 2012/01/17 06:00
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2012/05/23 06:00 [medline]
PHST- 2012/02/14 00:00 [pmc-release]
AID - 10.3109/00365521.2011.645501 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2012 Feb;47(2):136-47. doi: 10.3109/00365521.2011.645501.